Has This Top Pharma Company Found Its Next Billion-Dollar Product?
For decades, drugmakers have struggled to develop effective therapies to treat Alzheimer's disease, and though most have failed, researchers keep at it. That's hardly surprising. Alzheimer's disease affects some 6.5 million people in the U.S. alone, and even the one FDA-approved treatment for it is far from a cure.
Pharmaceutical giant Eli Lilly's (NYSE: LLY) potential Alzheimer's disease treatment is in late-stage clinical trials, and could be the next one to cross the regulatory finish line. And recently, Eli Lilly delivered positive news from the clinic that meaningfully improved its prospects for being able to compete in the Alzheimer's disease market.
Source Fool.com
